ClinicalTrials.gg
CompletedNCT02382640Updated Apr 29, 2016Results posted

Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

A Phase 1 interventional study of Febuxostat XR and Maalox Advance Regular Strength liquid in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-29.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the effect of antacid administration, and its timing, on the bioavailability of a single dose of febuxostat extended-release (XR) 80 mg.

Read the detailed description

The drug being tested in this study is called febuxostat extended-release (XR). Febuxostat XR is being tested to assess if antacids affect how the drug moves throughout the body. This study will look at lab safety and side effects in people who take febuxostat XR.

This cross-over study will enroll approximately 36 patients. Participants will be randomly assigned to one of four treatment sequences. All participants will receive the following study medications by the end of the study:

  • Febuxostat XR 80 mg capsules
  • Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent

All participants will be administered one dose of one or both of the study medications on Day 1 of four separate study periods.

This single-centre trial will be conducted in the United States. The overall time to participate in this study is up to 84 days. Participants will make 5 visits to the clinic including four 4-day periods of confinement to the clinic, and will be contacted by telephone 30 days after last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is a healthy adult male or female aged 18 to 55 years, inclusive, by check-in (Day-1 of Period 1)
  2. Weighs at least 50 kg (110 pounds), and has a (BMI) between 18.0 kg/m\^2 to 30 kg/m\^2, inclusive at Screening.
  3. Has estimated ≥90 mL/min

Exclusion criteria

Exclusion Criteria:

Any participant who meets any of the following criteria will not qualify for entry into the study:

  1. Has received any compound within 30 days prior to the first dose of study medication.
  2. Has received febuxostat in a previous clinical study or as a therapeutic agent.
  3. Has a known to any xanthine oxidase inhibitor, xanthine compounds or any component of the formulation of febuxostat tablets (see Package Insert) or to caffeine.
  4. Has a known hypersensitivity to aluminum, magnesium hydroxide, or any component of the formulation of antacid (Maalox Advanced Regular Strength or equivalent) (see Package Insert).
  5. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening visit or is unwilling to agree to abstain from alcohol and drugs throughout the study. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 30 days after participating in this study; or intending to donate ova during such time period.
  6. Has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (ie, a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis frequent [more than once per week] occurrence of heartburn, or any surgical intervention [eg, cholecystectomy]).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Sequence 1: ABDC

    Experimental: Sequence 1: ABDC Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and 20 mL Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL (hereafter referred as Maalox) or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 1 (A), followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 2 (B), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 3 (D), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 4 (C).

    Drug: Febuxostat XR · Drug: Maalox Advance Regular Strength liquid

  • Experimental
    Sequence 2: DACB

    Experimental: Sequence 2: DACB Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 3, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 4.

    Drug: Febuxostat XR · Drug: Maalox Advance Regular Strength liquid

  • Experimental
    Sequence 3: CDBA

    Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 3, followed by a 7-day washout period, followed by Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 4.

    Drug: Febuxostat XR · Drug: Maalox Advance Regular Strength liquid

  • Experimental
    Sequence 4: BCAD

    Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 3, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 4.

    Drug: Febuxostat XR · Drug: Maalox Advance Regular Strength liquid

Interventions

  • Febuxostat extended-release (XR) capsules

  • DrugMaalox Advance Regular Strength liquid

    Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for Febuxostat

    Time frame: Days 1 at multiple timepoints (up to 48 hours) post-dose

  2. AUC(0-tau): Area Under the Plasma Concentration-time Curve During the Dosing Interval for Febuxostat

    Time frame: Days 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  3. AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Febuxostat

    Time frame: Days 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose

  4. Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to 30 days after last dose of drug (Day 31 for each of the 4 periods)

  5. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Time frame: Day 1 up to 30 days after last dose of drug (Day 31 for each of the 4 periods)

  6. Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings

    Time frame: Day 1 up to 30 days after last dose of drug (Day 31 for each of the 4 periods)

  7. Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Evaluation

    Time frame: Day 1 up to 30 days after last dose of drug (Day 31 for each of the 4 periods)

  8. Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG)

    Time frame: Day 1 up to 30 days after last dose of drug (Day 31 for each of the 4 periods)

07

Results

Posted Apr 29, 2016

Participant flow

Participants took part in the study at 1 investigative site in United States from 23-Feb-15 to 04-May-15.

Intervention Period 1 (3 Days)
Participant flow — Intervention Period 1 (3 Days)
MilestoneRegimen A, Then B, Then D, Then CRegimen D, Then A, Then C, Then BRegimen C, Then D, Then B, Then ARegimen B, Then C, Then A, Then D
Started9999
Completed9999
Not completed0000
Washout Period 1 (7 Days)
Participant flow — Washout Period 1 (7 Days)
MilestoneRegimen A, Then B, Then D, Then CRegimen D, Then A, Then C, Then BRegimen C, Then D, Then B, Then ARegimen B, Then C, Then A, Then D
Started9999
Completed9999
Not completed0000
Intervention Period 2 (3 Days)
Participant flow — Intervention Period 2 (3 Days)
MilestoneRegimen A, Then B, Then D, Then CRegimen D, Then A, Then C, Then BRegimen C, Then D, Then B, Then ARegimen B, Then C, Then A, Then D
Started9999
Completed9999
Not completed0000
Washout Period 2 (7 Days)
Participant flow — Washout Period 2 (7 Days)
MilestoneRegimen A, Then B, Then D, Then CRegimen D, Then A, Then C, Then BRegimen C, Then D, Then B, Then ARegimen B, Then C, Then A, Then D
Started9999
Completed9999
Not completed0000
Intervention Period 3 (3 Days)
Participant flow — Intervention Period 3 (3 Days)
MilestoneRegimen A, Then B, Then D, Then CRegimen D, Then A, Then C, Then BRegimen C, Then D, Then B, Then ARegimen B, Then C, Then A, Then D
Started9999
Completed9999
Not completed0000
Washout Period 3 (7 Days)
Participant flow — Washout Period 3 (7 Days)
MilestoneRegimen A, Then B, Then D, Then CRegimen D, Then A, Then C, Then BRegimen C, Then D, Then B, Then ARegimen B, Then C, Then A, Then D
Started9999
Completed9999
Not completed0000
Intervention Period 4 (3 Days)
Participant flow — Intervention Period 4 (3 Days)
MilestoneRegimen A, Then B, Then D, Then CRegimen D, Then A, Then C, Then BRegimen C, Then D, Then B, Then ARegimen B, Then C, Then A, Then D
Started9999
Completed8999
Not completed1000
Withdrew: Laboratory abnormality1000

Outcome measures

PrimaryCmax: Maximum Observed Plasma Concentration for Febuxostat
Time frame:
Days 1 at multiple timepoints (up to 48 hours) post-dose
Reported as:
Mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for Febuxostat
nanogram per milliliter (ng/mL)Regimen ARegimen BRegimen CRegimen D
Cmax: Maximum Observed Plasma Concentration for Febuxostat883.58 ± 898.491075.08 ± 941.46765.89 ± 480.21456.42 ± 875.39
PrimaryAUC(0-tau): Area Under the Plasma Concentration-time Curve During the Dosing Interval for Febuxostat
Time frame:
Days 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
Reported as:
Mean · nanogram*hour per milliliter (ng*hr/mL)
AUC(0-tau): Area Under the Plasma Concentration-time Curve During the Dosing Interval for Febuxostat
nanogram*hour per milliliter (ng*hr/mL)Regimen ARegimen BRegimen CRegimen D
AUC(0-tau): Area Under the Plasma Concentration-time Curve During the Dosing Interval for Febuxostat4680.69 ± 2427.115877.99 ± 2888.94412.22 ± 1718.427316.21 ± 2811.1
PrimaryAUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Febuxostat
Time frame:
Days 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
Reported as:
Mean · ng*hr/mL
AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Febuxostat
ng*hr/mLRegimen ARegimen BRegimen CRegimen D
AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Febuxostat5901 ± 2739.926999.9 ± 2912.714844.33 ± 1918.737697.85 ± 2732.63
PrimaryNumber of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to 30 days after last dose of drug (Day 31 for each of the 4 periods)
Reported as:
Number · participants
Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsRegimen ARegimen BRegimen CRegimen D
TEAE2132
SAE0000
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Vital Signs
Time frame:
Day 1 up to 30 days after last dose of drug (Day 31 for each of the 4 periods)
Reported as:
Number · participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
participantsRegimen ARegimen BRegimen CRegimen D
Number of Participants With Clinically Significant Change From Baseline in Vital Signs0000
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Physical Examination Findings
Time frame:
Day 1 up to 30 days after last dose of drug (Day 31 for each of the 4 periods)
Reported as:
Number · participants
Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings
participantsRegimen ARegimen BRegimen CRegimen D
Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings0000
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Evaluation
Time frame:
Day 1 up to 30 days after last dose of drug (Day 31 for each of the 4 periods)
Reported as:
Number · participants
Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Evaluation
participantsRegimen ARegimen BRegimen CRegimen D
Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Evaluation0000
PrimaryNumber of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG)
Time frame:
Day 1 up to 30 days after last dose of drug (Day 31 for each of the 4 periods)
Reported as:
Number · participants
Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG)
participantsRegimen ARegimen BRegimen CRegimen D
Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG)0000

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regimen A—0/36 (0%)2/36 (5.6%)
Regimen B—0/36 (0%)1/36 (2.8%)
Regimen C—0/35 (0%)3/35 (8.6%)
Regimen D—0/36 (0%)2/36 (5.6%)
Most frequent other events
Most frequent other events
EventRegimen ARegimen BRegimen CRegimen D
DiarrhoeaGastrointestinal disorders1/360/361/350/36
NauseaGastrointestinal disorders0/360/361/350/36
HeadacheNervous system disorders0/360/361/350/36
Oral herpesInjury, poisoning and procedural complications1/360/360/350/36
MyalgiaMusculoskeletal and connective tissue disorders0/360/360/351/36
DizzinessNervous system disorders0/360/360/351/36
EcchymosisSkin and subcutaneous tissue disorders0/361/360/350/36

Baseline characteristics

The safety set was defined as all participants who were enrolled and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Regimen A, Then B, Then D, Then CRegimen D, Then A, Then C, Then BRegimen C, Then D, Then B, Then ARegimen B, Then C, Then A, Then DTotal
Mean37.8 ± 7.3634.7 ± 13.4231.7 ± 9.1835.8 ± 11.3835.0 ± 10.36
Sex: Female, Male
Sex: Female, Male(Participants)Regimen A, Then B, Then D, Then CRegimen D, Then A, Then C, Then BRegimen C, Then D, Then B, Then ARegimen B, Then C, Then A, Then DTotal
Female555621
Male444315
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Regimen A, Then B, Then D, Then CRegimen D, Then A, Then C, Then BRegimen C, Then D, Then B, Then ARegimen B, Then C, Then A, Then DTotal
Hispanic or Latino534517
Not Hispanic or Latino465419
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Regimen A, Then B, Then D, Then CRegimen D, Then A, Then C, Then BRegimen C, Then D, Then B, Then ARegimen B, Then C, Then A, Then DTotal
Black or African American124310
White865524
Multiracial01012
Smoking classification
Smoking classification(participants)Regimen A, Then B, Then D, Then CRegimen D, Then A, Then C, Then BRegimen C, Then D, Then B, Then ARegimen B, Then C, Then A, Then DTotal
Has never smoked898833
Is an ex-smoker10113
Alcohol classification
Alcohol classification(participants)Regimen A, Then B, Then D, Then CRegimen D, Then A, Then C, Then BRegimen C, Then D, Then B, Then ARegimen B, Then C, Then A, Then DTotal
Has never drunk245415
Is a current drinker41128
Is an ex-drinker343313
Xanthine/caffeine consumption
Xanthine/caffeine consumption(participants)Regimen A, Then B, Then D, Then CRegimen D, Then A, Then C, Then BRegimen C, Then D, Then B, Then ARegimen B, Then C, Then A, Then DTotal
Had xanthine/caffeine consumption553518
Had no xanthine/caffeine consumption446418
Female reproductive status
Female reproductive status(participants)Regimen A, Then B, Then D, Then CRegimen D, Then A, Then C, Then BRegimen C, Then D, Then B, Then ARegimen B, Then C, Then A, Then DTotal
Female of childbearing potential454417
Surgically sterile10124
N/A (participant is male)444315
08

Study locations

1 site
  • Austin, Texas 78744, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2015
First posted
Mar 9, 2015
Start
Mar 2015
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Apr 29, 2016
Last update
Apr 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02382640
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 9, 2015
Start date
Mar 2015
Primary completion
May 2015
Completion
May 2015
Results posted
Apr 29, 2016
Last update
Apr 29, 2016

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion